Incidental Use of Beta-Blockers Is Associated with Outcome of
Metastatic Colorectal Cancer Patients Treated with
Bevacizumab-Based Therapy: A Single-Institution Retrospective
Analysis of 514 Patients

J 2019

Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients

FIALA, Ondrej, Pavel OSTASOV, Ondrej SOREJS, Vaclav LISKA, Tomáš BÜCHLER et. al.

Základní údaje

Originální název

Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients

Autoři

FIALA, Ondrej (203 Česká republika, garant), Pavel OSTASOV (203 Česká republika), Ondrej SOREJS (203 Česká republika), Vaclav LISKA (203 Česká republika), Tomáš BÜCHLER (203 Česká republika), Alexandr POPRACH (203 Česká republika, domácí) a Jindrich FINEK (203 Česká republika)

Vydání

Cancers, BASEL, MDPI, 2019, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.126

Kód RIV

RIV/00216224:14110/19:00112964

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/cancers11121856

UT WoS

000507382100035

Klíčová slova anglicky

colorectal cancer; bevacizumab; beta-blocker; outcome; hypertension

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 2. 2020 14:37, Mgr. Tereza Miškechová

Anotace

V originále

Background: Beta-adrenergic signalling plays an important role in several cancer-related processes, including angiogenesis. The impact of beta-blocker use on prognosis of cancer patients treated with antiangiogenic agents is unclear. The aim of this study was to evaluate the association between the incidental use of beta-blockers and the outcomes of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based therapy. Methods: Clinical data from 514 mCRC patients treated with bevacizumab between 2005 and 2019 were analysed retrospectively. The association of progression-free survival (PFS) and overall survival (OS) with the incidental use of beta-blockers and other common antihypertensive drugs was assessed. Results: The median PFS and OS for patients using beta-blockers was 11.40 (95% confidence interval (CI) 10.10-13.61) months and 26.8 (95% CI 22.2-32.2) months compared with 8.30 (95% CI 7.80-9.57) and 21.0 (95% CI 17.8-23.8) months for patients not using beta-blockers (p = 0.006 and p = 0.009, respectively). In the Cox multivariate analysis, the use of beta-blockers was a significant factor predicting both PFS (hazard ratio (HR) = 0.763 (95% CI 0.606-0.960), p = 0.021) and OS (HR = 0.730 (95% CI 0.560-0.951), p = 0.020). Conclusions: The results of the present retrospective study suggest that there is a significant association between the use of beta-blockers and favourable outcomes of mCRC patients treated with bevacizumab-based therapy.

Citovat

FIALA, Ondrej, Pavel OSTASOV, Ondrej SOREJS, Vaclav LISKA, Tomáš BÜCHLER, Alexandr POPRACH a Jindrich FINEK. Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. Cancers. BASEL: MDPI, 2019, roč. 11, č. 12, s. 1-13. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers11121856.

@article{1623236,
   author = {Fiala, Ondrej and Ostasov, Pavel and Sorejs, Ondrej and Liska, Vaclav and Büchler, Tomáš and Poprach, Alexandr and Finek, Jindrich},
   article_location = {BASEL},
   article_number = {12},
   doi = {http://dx.doi.org/10.3390/cancers11121856},
   keywords = {colorectal cancer; bevacizumab; beta-blocker; outcome; hypertension},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients},
   url = {http://dx.doi.org/10.3390/cancers11121856},
   volume = {11},
   year = {2019}
}

TY  - JOUR
ID  - 1623236
AU  - Fiala, Ondrej - Ostasov, Pavel - Sorejs, Ondrej - Liska, Vaclav - Büchler, Tomáš - Poprach, Alexandr - Finek, Jindrich
PY  - 2019
TI  - Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients
JF  - Cancers
VL  - 11
IS  - 12
SP  - 1-13
EP  - 1-13
PB  - MDPI
SN  - 20726694
KW  - colorectal cancer
KW  - bevacizumab
KW  - beta-blocker
KW  - outcome
KW  - hypertension
UR  - http://dx.doi.org/10.3390/cancers11121856
L2  - http://dx.doi.org/10.3390/cancers11121856
N2  - Background: Beta-adrenergic signalling plays an important role in several cancer-related processes, including angiogenesis. The impact of beta-blocker use on prognosis of cancer patients treated with antiangiogenic agents is unclear. The aim of this study was to evaluate the association between the incidental use of beta-blockers and the outcomes of patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-based therapy. Methods: Clinical data from 514 mCRC patients treated with bevacizumab between 2005 and 2019 were analysed retrospectively. The association of progression-free survival (PFS) and overall survival (OS) with the incidental use of beta-blockers and other common antihypertensive drugs was assessed. Results: The median PFS and OS for patients using beta-blockers was 11.40 (95% confidence interval (CI) 10.10-13.61) months and 26.8 (95% CI 22.2-32.2) months compared with 8.30 (95% CI 7.80-9.57) and 21.0 (95% CI 17.8-23.8) months for patients not using beta-blockers (p = 0.006 and p = 0.009, respectively). In the Cox multivariate analysis, the use of beta-blockers was a significant factor predicting both PFS (hazard ratio (HR) = 0.763 (95% CI 0.606-0.960), p = 0.021) and OS (HR = 0.730 (95% CI 0.560-0.951), p = 0.020). Conclusions: The results of the present retrospective study suggest that there is a significant association between the use of beta-blockers and favourable outcomes of mCRC patients treated with bevacizumab-based therapy.
ER  -

FIALA, Ondrej, Pavel OSTASOV, Ondrej SOREJS, Vaclav LISKA, Tomáš BÜCHLER, Alexandr POPRACH a Jindrich FINEK. Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients. \textit{Cancers}. BASEL: MDPI, 2019, roč.~11, č.~12, s.~1-13. ISSN~2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers11121856.

Podrobný výpis o publikaci